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surface, and treatment with APD reduced the osteoblast sur-Phosphate depletion in the rat: Effect of bisphosphonates and
face (LPD vs. LPD 1 APD, 38 6 4 vs. 4 6 2%, P , 0.05, andthe calcemic response to PTH.
ND vs. ND 1 APD, 20 6 2 vs. 5 6 2%, P , 0.05) and markedlyBackground. The removal of phosphate from the diet of the
altered osteoclast morphology by inducing cytoplasmic vacu-growing rat rapidly produces hypercalcemia, hypophosphate-
oles.mia, hypercalciuria, and hypophosphaturia. Increased calcium
efflux from bone has been shown to be the important cause Conclusions. (a) Phosphate depletion induced hypercalce-
of the hypercalcemia and hypercalciuria. It has been proposed mia and hypercalciuria that were not reduced by APD adminis-
that the increased calcium efflux from bone is osteoclast medi- tration. (b) The calcemic response to PTH was reduced in
ated. Because bisphosphonates have been shown to inhibit phosphate-depleted rats and was unaffected by APD adminis-
osteoclast-mediated bone resorption, this study was performed tration in normal and phosphate-depleted rats, and (c) APD
to determine whether bisphosphonate-induced inhibition of administration markedly changed bone histology without af-
osteoclast function changed the biochemical and bone effects fecting the biochemical changes induced by phosphate deple-
induced by phosphate depletion. tion.
Methods. Four groups of pair-fed rats were studied: (a) low-
phosphate diet (LPD; phosphate less than 0.05%), (b) LPD
plus the administration of the bisphosphonate Pamidronate
The removal of inorganic phosphate from the diet of(APD; LPD 1 APD), (c) normal diet (ND, 0.6% phosphate),
and (d) ND 1 APD. All diets contained 0.6% calcium. A high the growing rat, even though all other dietary constit-
dose of APD was administered subcutaneously (0.8 mg/kg) uents remain normal, rapidly produces hypercalcemia,
two days before the start of the study diet and on days 2, 6, hypercalciuria, hypophosphatemia, and a urine virtuallyand 9 during the 11 days of the study diet. On day 10, a
free of phosphorus. These biochemical changes have24-hour urine was collected, and on day 11, rats were either
been shown to occur in both normal [1–5] and azotemicsacrificed or received an additional APD dose before a 48-
hour parathyroid hormone (PTH) infusion (0.066 mg/100 g/hr) rats [6]. The primary mechanism responsible for the
via a subcutaneously implanted miniosmotic pump. changes in calcium metabolism in phosphate depletion
Results. Serum and urinary calcium were greater in the LPD has been shown to be an increase in calcium efflux fromand LPD 1 APD groups than in the ND and ND 1 APD
bone that has been postulated to be caused by an increasegroups [serum, 11.12 6 0.34 and 11.57 6 0.45 vs. 9.49 6 0.17
in osteoclast number and efficiency [2–4, 7, 8]. Previousand 9.48 6 0.15 mg/dl (mean 6 se), P , 0.05; and urine, 8.78 6
2.74 and 16.30 6 4.68 vs. 0.32 6 0.09 and 0.67 6 0.28 mg/24 studies in which calcium balance was performed have
hr, P , 0.05]. Serum PTH and serum and urinary phosphorus shown that increased intestinal absorption of calcium is
were less in the LPD and LPD 1 APD than in the ND and
not a major factor in the development and maintenanceND 1 APD groups (P , 0.05). The calcemic response to PTH
of the hypercalcemia and hypercalciuria [1, 5, 9].was less (P , 0.05) in the LPD and LPD 1 APD groups than
in the ND group and was less (P 5 0.05) in the LPD 1 APD Bisphosphonates, which are biologically active ana-
than in the ND 1 APD group. Bone histology showed that logues of endogenous pyrophosphates, have been shown
phosphate depletion increased the osteoblast and osteoclast to have a potent inhibitory effect on bone resorption
[10]. As such, bisphosphonates have been used in both
clinical and experimental studies to treat bone-mediatedKey words: bone, calcitriol, hypercalcemia, hypophosphatemia, osteo-
clast, calcium metabolism. hypercalcemia and to decrease accelerated bone resorp-
tion. These studies have included conditions such as tu-
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[15], and bone loss in ovariectomized animals [16] and to PTH [23, 24]. PTH was infused at a rate of 0.066 mg/
100 g body wt/hr; in a previous study, this dose of PTHimmobilized rats [17], as well as during the use of reti-
noids [18], calcitriol [19], and cyclosporine [20]. was shown to be three times the dose required to main-
tain a normal serum calcium, phosphorus, and calcitriolThis study was performed to determine whether (a)
bisphosphonate-induced inhibition of osteoclast function level in rats maintained on a 0.6% calcium and 0.6%
phosphorus diet [25]. To ensure the proper function ofchanged the biochemical and bone effects induced by
phosphate depletion and (b) phosphate depletion and the miniosmotic pump, each pump was used in three rats
from different groups. At the end of the 48-hour PTHbisphosphonate treatment affected the calcemic re-
sponse to parathyroid hormone (PTH). infusion, rats were anesthetized and sacrificed by punc-
ture of the abdominal aorta.
After sacrifice, the ilium was detached from the skele-
METHODS
ton and processed as previously described [26]. Five mi-
Male Wistar rats weighing 160 to 180 g were used for crometer Goldner-stained sections of cancellous bone
the study. During procedures, rats were anesthetized were examined for cellular detail, osteoid, and mineral-
with intraperitoneally administered ketamine (7.5 mg/ ized bone. In each treatment group before and after PTH
100 g, Ketaset; Fort Dodge Laboratories, Fort Dodge, infusion, the quantitation of a randomly selected sample
IA, USA) and xylazine (0.5 mg/100 g, AnaSed; Lloyd was performed at a magnification of 3400 with a Merz-
Laboratories, Shenandoah, IA, USA). Rats were housed Schenk eyepiece reticle. The assessment of the bone
in individual cages, given 14 g of food daily, and allowed was performed by one of the authors (A.J.F.) without
free access to water. knowledge of the different groups.
Two diets were used during the study. Both diets were Serum and urinary calcium and phosphorus were mea-
provided by the same supplier (ICN, Cleveland, OH, sured with specific kits (Sigma, St. Louis, MO, USA).
USA) and contained 0.6% calcium and 100 IU of vitamin Serum and urinary creatinine were measured with a cre-
D per 100 g of diet; the dietary phosphate content was atinine analyzer (Beckman, Fullerton, CA, USA). Serum
either less than 0.05% [low-phosphate diet (LPD)] or PTH was measured with an immunoradiometric assay
0.6% [normal diet (ND)]. The study design in the four specific for intact rat PTH (Nichols, San Juan Capistrano,
groups of pair-fed rats is shown in Figure 1. Two groups CA, USA). Serum calcitriol was measured with a radio-
received an LPD, and two groups received an ND. In one receptor assay by Nichols Institute; because of the need
LPD and one ND group, the bisphosphonate 3-amino-1- for a large aliquot of serum, calcitriol was only measured
hydroxypropylidene (APD; Pamidronate; Novartis, Sum- in rats sacrificed at the end of the study diet (day 11).
mit, NJ, USA) was administered subcutaneously two
days before the start of the study diet and on days 2, 6, Statistics
and 9 during the 11 days of the study diet. The dose Comparisons of the serum and urinary data among
used, 0.8 mg/kg, has been shown to be a high dose [21, the four groups were assessed by one-way analysis of
22] and was intentionally chosen for this reason. The variance followed by a post hoc test, the Fisher least
four groups of rats studied were (a) LPD (N 5 16), (b) significant difference, for multiple comparisons. An un-
LPD 1 APD (N 5 15), (c) ND (N 5 15), and (d) ND 1 paired t-test was used for the comparison between two
APD (N 5 15). The effect of fasting on the serum calcium groups. A P value of less than 0.05 was considered sig-
and phosphorus levels was also evaluated. In approxi- nificant. Results are expressed as the mean 6 se.
mately one half of the rats in each group, blood was
obtained at sacrifice on day 11 after an overnight fast or
RESULTStwo to four hours after feeding.
Between days 10 and 11, a 24-hour urine sample was The serum calcium, phosphorus, and PTH and the
body weight at the end of the study diet are shown incollected in a metabolic cage. After being anesthetized
on day 11, rats were either (a) sacrificed by exsanguina- Table 1. When the fed and fasted groups were combined,
the serum calcium was greater (P , 0.05) and serumtion from the abdominal aorta or (b) had blood obtained
from the tail vein after which a miniosmotic pump phosphorus and PTH were less (P , 0.05) in the two
groups (LPD and LPD 1 APD) on the LPD. The body(Model 2001; Alza, Palo Alto, CA, USA) containing 1-34
rat PTH (Bachem, Torrance, CA, USA) was implanted weight was similar in the four groups. The groups were
also separated according to whether rats were fed orsubcutaneously. In rats used to evaluate the calcemic
response to PTH, an additional dose of APD was given fasted before blood was obtained on the morning of day
11. In the fed group, serum calcium was greater, andon the morning of day 11. During the 48-hour PTH
infusion, rats received a calcium-free, 0.16% phosphate serum phosphorus and PTH were less in the LPD and
LPD 1 APD groups than the other two groups. In thediet to minimize gut calcium absorption and to have a
uniform effect of phosphorus on the calcemic response fasted groups, the only significant difference was a lower
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Fig. 1. Schematic diagram of the study design.
Table 1. Serum chemistries and body weight on day 11
LPD LPD 1 APD ND ND 1 APD ANOVA
Combined
N 16 15 15 15
Calcium mg/dl 11.1260.34 11.57 60.45 9.49 60.17a 9.4860.15a ,0.001
Phosphorus mg/dl 7.5260.54 7.00 60.55 8.4960.28c 9.0160.55b 50.03
PTH pg/mld 1063 11 64 75 69a 8067a ,0.001
Weight grams 18964 184 64 190 64 188 65 5NS
Fed
N 9 8 8 9
Calcium mg/dl 11.9260.36 12.63 60.36 9.69 60.27a 9.5760.23a ,0.001
Phosphorus mg/dl 6.2760.56 6.66 60.84 8.64 60.33a 9.5260.62a 50.002
PTH pg/mld 761 8 61 69615a 7464a ,0.001
Fasted
N 7 7 7 6
Calcium mg/dl 10.0960.29 10.50 60.60 9.27 60.17 9.34 60.17 50.09
Phosphorus mg/dl 9.1460.51 7.39 60.65 8.32 60.45 8.31 61.06 5NS
PTH pg/mld 1566 15 69 82 610a 90616a ,0.001
Data are mean 6 se. Abbreviations are: LPD, low phosphorus diet; LPD 1 APD, low phosphorus diet 1 pamidronate; ND, normal diet; ND 1 APD, normal
diet 1 pamidronate.
a P , 0.01 vs. LPD and LPD 1 APD
b P , 0.05 vs. LPD and LPD 1 APD
c P , 0.05 vs. LPD 1 APD
d Number of PTH values are in combined group, 11 (LPD), 10 (LPD 1 APD), 14 (ND), and 15 (ND 1 APD); in the fed and fasted groups, the respective numbers
are 7 and 4 (LPD), 6 and 4 (LPD 1 APD), 8 and 6 (ND), and 9 and 6 (ND 1 APD).
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cium excretion was even greater in the LPD 1 APD
than the LPD group (P , 0.05).
Because a wide range of serum calcium values were
present when the serum calcium was obtained at the
end of the study diet, it was possible to show that the
relationship between serum calcium and PTH was best
characterized by a sigmoidal-like curve (Fig. 3).
As shown in Figure 4, the calcemic response to PTH
(D calcium) was greater in the ND group than the two
LPD groups and greater in the ND 1 APD than the
LPD 1 APD group (ANOVA, P 5 0.02); the difference
between the LPD and the ND 1 APD groups ap-
proached significance (P 5 0.08). The comparison for
the pre-PTH infusion serum calcium approached but did
not attain significance (ANOVA, P 5 0.07). The post-
PTH infusion serum calcium value was not different
among the groups. Creatinine clearances determined im-
mediately before the PTH infusion were not different
(ANOVA, P 5 0.73). Similarly, serum creatinine values
at the end of the PTH infusion were not different.
Bone histomorphometry and histology are shown in
Table 3 and Figures 5 and 6. Phosphate depletion in-
creased the osteoblast surface (Ob.S/BS), osteoid sur-
face, osteoclast surface, eroded surface, osteoclasts/mm2,
and the osteoid volume as compared with rats on an NDFig. 2. The four groups were subdivided according to whether the rats
were fed ( ) or fasted ( ) at the time blood was obtained at the end (LPD vs. ND). An example of the increase in osteoblast
of 11 days of the study diet. The serum calcium is shown in (A), and surface in phosphate-depleted rats (LPD) is shown in
the serum phosphorus is shown in (B). LPD, low-phosphate diet; LPD 1
Figure 5A. The administration of APD reduced the os-APD, low-phosphate diet plus the bisphosphonate APD; ND, normal
diet; and ND 1 APD, normal diet plus APD. *P , 0.01 fed vs. fasted teoblast surface and osteoid surface both in phosphate-
pair. depleted rats (Fig. 5B) and in rats on an ND; although
the latter is not depicted in the figure, quantitative data
are shown in Table 3. The APD-induced reduction in
osteoblast surface was proportionally greater than the
PTH in the LPD and LPD 1 APD groups than the
reduction in osteoid surface. This result can be appreci-
other two groups. As shown in Figure 2, when the serum ated when the osteoblast surface is expressed as a per-
calcium and phosphorus levels in the fed and fasted ani- centage of the osteoid surface (OB.S/OS; Table 3). As
mals were compared for each group, the serum calcium compared with normal osteoclasts (Fig. 6A), phosphate
was less during fasting in both the LPD and LPD 1 depletion resulted in multinucleated osteoclasts that
APD groups (Fig. 2A). Only in the LPD group was the were much larger than those in normal rats (Fig. 6B).
serum phosphorus greater during fasting (Fig. 2B). Although the administration of APD did not reduce the
At the end of the study diet (day 11), serum calcitriol osteoclast surface or osteoclasts/mm2, APD markedly
values for the four groups were 291 6 39 (LPD, N 5 altered the morphology of the osteoclast both in phos-
8), 402 6 27 (LPD 1 APD, N 5 8), 198 6 7 (ND, N 5 phate-depleted and normal rats. The administration of
8), and 345 6 33 pg/ml (ND 1 APD, N 5 4). Among APD to phosphate-depleted rats did not diminish the
the four groups, these values were different by analysis giant size of the osteoclasts, but did result in a diffusely
of variance (ANOVA; P , 0.001) and were greater (P , vacuolated cytoplasm in virtually all osteoclasts (Fig. 6
0.05) by post hoc test in the LPD than the ND group, C, D), some of which also had pyknotic nuclei (Fig. 6D).
in the LPD 1 APD than the LPD group, and in the In rats on an ND receiving APD (ND 1 APD), the
ND 1 APD than the ND group. cytoplasm was also vacuolated, but the osteoclasts did
The creatinine clearance was similar among the four not increase in size (not shown).
groups, and urine volume was greater (P , 0.05) in the With certain minor exceptions, the 48-hour PTH infu-
two LPD groups (Table 2). Urinary calcium excretion sion did not change bone morphology. As shown in Table
was much greater (P , 0.05), and urinary phosphorus 3, the only observed difference in pre- and post-PTH
excretion was much less (P , 0.05) and essentially negli- infusion was a reduction in the osteoblast surface
(Ob.S/BS) in the ND group. No other significant differ-gible in the two LPD groups; interestingly, urinary cal-
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Table 2. Urinary data obtained between day 10 and day 11
LPD LPD 1 APD ND ND 1 APD ANOVA
N 16 15 15 15
Urinary calcium mg/24 hr 8.7862.74 16.3064.68a 0.3260.09b 0.6760.28b ,0.001
Urinary phosphorus mg/24 hr 0.2160.02 0.25 60.03 22.163.3b 22.963.8b ,0.001
Fractional excretion of phosphorus % 0.3660.07 0.48 60.12 27.462.8b 25.562.0b ,0.001
Urinary volume ml/24 hr 13.561.2 18.0 62.6a 5.260.5b 7.461.2b ,0.001
Creatinine clearance ml/min/kg 3.8860.37 3.99 60.53 3.5460.19 4.34 60.66 5NS
Data are mean 6 se. Abbreviations are in Table 1.
a P , 0.05 vs. LPD
b P , 0.05 vs. LPD and LPD 1 APD
Fig. 4. Calcemic response to a 48-hour parathyroid hormone (PTH)
infusion, defined as the increase in serum calcium from baseline
(D serum calcium; h), as well as the pre-PTH ( ) and post-PTH ( )
Fig. 3. Relationship between serum calcium and parathyroid hormone infusion serum calcium values are shown for the four groups: LPD (low
(PTH) in blood collected at the end of the study diet is shown for the phosphate diet; N 5 8), LPD 1 APD (LPD 1 Pamidronate; N 5 8),
four groups of rats. Symbols are: ( ) low phosphate diet (LPD); ( ) ND (normal diet; N 5 6), and ND 1 APD (N 5 7). The one-way
LPD 1 Pamidronate (APD); (s) normal diet (ND); (d) ND 1 APD. analysis of variance for the D calcium comparison among the four groups
A sigmoidal curve would appear to best characterize the relationship. was P 5 0.02. In addition to the differences shown in the figure, the
comparison between the LPD and ND groups approached but did not
attain significance (P 5 0.08). The one-way analysis of variance for the
pre-PTH serum calcium value among the four groups approached but
did not attain significance (P 5 0.07). *P , 0.05 vs. LPD and LPD 1ences were observed, although a tendency for a reduction APD; 1P , 0.05 vs. LPD 1 APD.
in osteoid volume was present in the LPD (P 5 0.07)
and ND (P 5 0.08) groups.
However, an intriguing observation is that the increase
DISCUSSION in bone resorption induced by phosphate depletion com-
mences even before an increase in the number of osteo-This study again shows that phosphate depletion in
the growing rat produces hypercalcemia, hypophospha- clasts is observed [3, 4, 8]. In the past, this has been
attributed to a greater efficiency of existing osteoclaststemia, hypercalciuria, and hypophosphaturia. Fasting,
even for a short time, reduced the magnitude of hypercal- to resorb bone [3, 4, 8]. However, it could also be argued
that osteoclast independent bone resorption is impor-cemia and hypophosphatemia. The administration of
APD reduced the osteoblast surface and dramatically tant. Parfitt and others have provided compelling experi-
mental data that support the concept that bone remodel-altered osteoclast morphology, but did not prevent the
hypercalcemia and hypercalciuria induced by phosphate ing and the mechanism for the regulation of plasma
calcium are different, with the former dependent on cel-depletion. Finally, the calcemic response to PTH was
reduced in phosphate-depleted rats, and APD adminis- lular bone surfaces and the latter on quiescent bone
surfaces [28–33]. Similarly, in previous studies in whichtration did not reduce the calcemic response to PTH in
normal or phosphate-depleted rats. dynamic measurements of bone were performed in grow-
ing rats, one of the authors (A.J.F.) noted that the tetra-Several previous studies have shown that phosphate
depletion in the growing rat produces hypercalcemia and cycline-labeled bone surface, which should represent
bone mineralization, was often greater than the osteoidhypercalciuria [1–5]. Increased bone resorption, as dem-
onstrated by bone histology [3, 4, 8] and radioisotopes surface. Thus, it is possible that the rapid loss of bone
calcium observed with phosphate depletion [7, 8, 34][2, 27], is considered to be the most important factor in
the development of hypercalcemia and hypercalciuria. may be due to changes in the physicochemical exchange
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Table 3. Bone histomorphometric data
PTH infusion LPD LPD 1 APD ND ND 1 APD ANOVA
Osteoblast surface % Pre 37.764.2 4.162.3a 20.362.1ab 5.262.4a ,0.001
(Ob.S/BS) Post 26.664.1 5.963.0a 11.162.1ad 1.560.5ac ,0.001
Osteoblast surface % Pre 7964 1965a 8567b 40615ac ,0.001
(Ob.S/OS) Post 7465 37618 75 612 28612ac 50.04
Osteoid surface % Pre 46.762.9 21.864.2a 24.965.0a 11.162.5ac ,0.001
(OS/BS) Post 35.564.4 15.661.4a 15.562.6a 8.662.7ac ,0.001
Quiescent surface % Pre 35.165.2 61.860.9a 66.663.4a 79.161.7abc ,0.001
(QS/BS) Post 45.263.5 63.765.1a 73.263.0a 76.063.9ab ,0.001
Osteoclast surface % Pre 14.362.4 13.162.7 5.5 61.4ab 7.761.4a 50.03
(Oc.S/BS) Post 13.961.5 15.963.5 8.0 63.4 12.263.7 5NS
Eroded surface % Pre 18.362.4 16.464.4 8.562.0a 9.861.6a 50.04
(ES/BS) Post 19.462.3 20.663.6 11.3 63.9 15.5 64.6 5NS
Osteoclast number/mm2 Pre 4.860.7 5.261.7 1.4 60.4ab 2.360.4ab 50.02
(N.Oc/T.A.) Post 4.360.6 5.361.3 2.1 60.8 3.8 61.0 5NS
Osteoid volume % Pre 14.262.2 8.262.1a 4.261.3a 3.460.4a 50.002
(OV/BV) Post 7.662.2 6.461.4 1.6 60.6ab 2.761.1a 50.03
Bone volume % Pre 8.861.0 16.466.5 7.9 61.1 10.962.7 5NS
(BV/TV) Post 10.161.4 13.062.2 10.6 61.6 9.5 61.6 5NS
Data are mean 6 se. Definitions of group abbreviations are in Table 1. Pre is Day 11 and Post is Day 13. Definitions of the measured parameters are: (1) osteoblast
surface, the fraction of trabecular bone surface covered by osteoblasts (Ob.S/BS); (2) osteoblast surface, the fraction of total osteoid surface covered by osteoblasts
(Ob.S/OS); (3) osteoid surface, the fraction of trabecular bone surface covered by osteoid (OS/BS); (4) quiescent surface, the fraction of trabecular bone surface
covered with lining cells, QS/BS); (5) osteoclast surface, the fraction of trabecular bone surface covered by osteoclasts (Oc.S/BS); (6) eroded surface, the fraction of
resorption surface covered by resorption cavities (ES/BS); (7) osteoclast number, the number of osteoclasts per square millimeter of cancellous bone (N.Oc./T.A.);
(8) osteoid volume, the fraction of trabecular bone volume occupied by osteoid (OV/BV); and (9) bone volume, the fraction of cancellous bone (tissue volume)
occupied by trabecular bone (BV/TV).
a P , 0.05 vs LPD, b vs. LPD 1 APD, c vs. ND
d vs. Pre-PTH infusion
PrePTH 2 LPD (n 5 5); LPD 1 APD (n 5 4); ND (n 5 4); ND 1 APD (n 5 4)
PostPTH 2 LPD (n 5 4); LPD 1 APD (n 5 4); ND (n 5 4); ND 1 APD (n 5 4)
process along the quiescent bone surface, rather than a tions that neither dietary calcium restriction [27] nor
vitamin D deficiency [38, 39] prevent hypercalcemia andspecific effect on the osteoclast. In this study, the magni-
tude of hypercalcemia was similar between the LPD and hypercalciuria in rats on a phosphate-depleted diet. Fi-
nally, studies in patients and mice with X-linked hypo-LPD 1 APD groups, even though APD administration
reduced the osteoblast surface and dramatically altered phosphatemia serve to confirm that independent of
calcitriol, enhanced calcium efflux from bone is the im-osteoclast morphology.
The mechanism by which phosphate depletion in- portant factor in the development of hypercalcemia and
hypercalciuria; in these studies, dietary phosphate re-creases calcium efflux from bone is not known but must
be cell-mediated or involve the physicochemical ex- striction increased serum calcium and induced fasting
hypercalciuria even though serum calcitriol values de-change of calcium. Recent reviews have suggested that
the therapeutic effects of bisphosphonates depend more creased [40, 41].
In this study, an overnight fast reduced the magnitudeon inhibition of abnormal bone resorption than on nor-
mal bone remodeling [35]. Moreover, it has been re- of hypercalcemia and hypophosphatemia in phosphate-
depleted rats. This finding has been shown in severalported that the primary effect of bisphosphonates is at
the cellular level, resulting in a reduction of osteoclast previous studies [5, 34, 42]. It is also possible that the
increase in serum phosphorus associated with fastingactivity [36]. Thus, bisphosphonates would be expected
to have a greater effect if the increased calcium efflux may have contributed to the lower serum calcium by
reducing calcium efflux from bone.were osteoclast-mediated than if it were due to a physico-
chemical process along the quiescent bone surface. As expected, dietary phosphate restriction increased
serum calcitriol levels. In addition, bisphosphonate ad-Dietary phosphate restriction increases calcitriol levels
[37], and the latter may enhance gut calcium absorption. ministration independently increased serum calcitriol
levels in rats on both normal and phosphate-depletedHowever, calcium balance studies have not detected a
decrease in fecal calcium in growing rats on a phosphate- diets. In previous studies, bisphosphonate administration
has been shown to increase serum calcitriol levels in bothdepleted diet [1, 2, 9]. Moreover, in this study, serum
and urinary calcium values were much greater in the normal and parathyroidectomized rats [43, 44]. How-
ever, the mechanism for the bisphosphonate-induced in-LPD than in the ND 1 APD group, despite similar serum
calcitriol values. Also suggesting that enhanced gut cal- crease in serum calcitriol is not known. Finally, we
believe that the observation that bisphosphonate ad-cium absorption is not a major factor are the observa-
Fig. 5. (A) In rats on the low phosphate diet (LPD group), the osteoblast surface (black arrow) was increased. As shown in the inset, the
osteoblasts (black arrow) were in general cuboidal, and osteoblast incorporation into the osteoid matrix was commonly observed. (B) The
administration of APD resulted in a marked decrease in the osteoblast surface. A representative example of an osteoid seam devoid of osteoblasts
is shown in a rat on the low-phosphate diet (LPD 1 APD group). Abbreviations are: OS, osteoid; MB, mineralized bone. For comparison of size,
40 micron bars are included in each panel.
Fig. 6. (A) Two osteoclasts (black arrows) on the bone surface in a rat on a normal diet (ND group). (B) The osteoclasts (black arrow) in rats
on a phosphate-depleted diet (LPD group) were multinucleated and much larger than those in the rats on a normal diet. (C) In rats on the low-
phosphate diet receiving APD (LPD 1 APD group), the osteoclasts (black arrow) were large and multinucleated. The osteoclast is on the bone
surface and includes and extends beyond the area that is not in focus (the two arrows). Note the diffusely vacuolated appearance of the cytoplasm.
(D) Another giant, multinucleated osteoclast from a rat on the low-phosphate diet and receiving APD (LPD 1 APD group). In addition to the
vacuolated cytoplasm, the osteoclast is distinguished by many nuclei that are pyknotic. For size comparison, a megakaryocyte is seen immediately
above the giant osteoclast. For comparison of size, 15 micron bars are included in each panel.
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ministration further increases serum calcitriol values be- data are less convincing because the 0.2% phosphorus
diet used may not have induced phosphate depletion;yond that achieved with dietary phosphate restriction is
being reported for the first time. the rats were studied two days after thyroparathyroidec-
tomy, and the duration of the PTH infusion was only 90The administration of the bisphosphonate APD did
not affect the development of hypercalcemia and hyper- minutes. It is also likely that in our study the degree of
skeletal resistance to PTH in the phosphate-depletedcalciuria. This result was somewhat unexpected because
bisphosphonates have been used successfully to decrease group may have been underestimated by the final serum
calcium because, in these rats, PTH suppression by hy-bone resorption in a number of clinical and experimental
conditions [11–20]. The dose of APD given should have percalcemia maximizes urinary calcium excretion. Con-
versely, in the normal rats, basal PTH secretion functionsbeen adequate because it reduced the osteoid and osteo-
blast surface and altered osteoclast morphology. An ef- to maintain urinary calcium excretion at relatively low
values. Because urinary calcium excretion was more thanfect of APD on the osteoid and osteoblast surface has
also been reported in previous similar short-term studies 20-fold greater in the phosphate-depleted than in the
normal rat, it would be expected that PTH administra-in animals [45, 46] and may be the result of a relatively
continuous rather than an intermittent exposure to bis- tion in the former group should result in a significant
reduction in calcium excretion, which because of thephosphonates [47]. APD administration also produced
vacuoles in the cytoplasm. This finding has been de- much greater magnitude of urinary calcium excretion
in the phosphate-depleted rat, should increase serumscribed in osteoclasts exposed to high levels of bisphos-
phonates and has been suggested to be indicative of calcium more in the phosphate-depleted than in the
normal rat. Such a result has been shown previouslyosteoclasts undergoing apoptosis [48–50]. Although bis-
phosphonates bind to the bone crystal surface by chemi- during PTH administration in the phosphate-depleted
animal [58].sorption to calcium, their precise mode of inhibition of
bone resorption is believed to be cellular [51]. The inhibi- An unexpected finding was that APD administration
did not reduce the calcemic response to PTH in normaltory effect of bisphosphonates is likely due to a direct
effect on the osteoclast [51–54], which could be due to rats. In an earlier study, Doppelt, Neer and Potts re-
ported that pretreatment with dichloromethylene bis-either the induction of apoptosis [48–51] or changes in
the actin ring structure of the osteoclast [51, 54]. More- phosphonate completely blocked PTH-induced hyper-
calcemia [59]. In more recent studies, Azuma et alover, an indirect effect in which bisphosphonates act on
the osteoblast to inhibit the osteoclast has also been showed that alendronate in doses with a biological po-
tency of approximately 10 and 50 times greater than thesuggested [10, 51]. The dramatic alteration of osteoclast
morphology in this study and the reduction of osteoclast dose of APD used in our study modestly reduced serum
calcium in normal and PTH-supplemented rats [22, 60].function in previous studies by bisphosphonate adminis-
tration both strongly suggest that osteoclast-mediated Besides the marked differences in equivalent doses of
bisphosphonate, other differences were present betweenbone resorption was reduced in our study. Moreover,
because our study showed that high-dose APD adminis- the two studies. In our study, PTH was administered
continuously for two days, as opposed to a single intrave-tration reduced the osteoblast surface, any potential
osteoblast-mediated stimulation of osteoclast function nous dose. Furthermore, after accounting for the differ-
ence in biological activity between bovine and rat PTH[10, 51] should also have been minimized.
In our study, the reduced calcemic response to PTH [61], the total daily PTH dose was approximately 50%
greater in our study. Another potentially important dif-in the phosphate-depleted groups was not due to a de-
crease in renal function. Although it might have been ference was that standard rat chow, which usually has a
phosphorus content between 0.6% and 0.9%, was usedexpected that persistent hypercalcemia and hypercalci-
uria in the phosphate-depleted rats would have resulted in the studies by Azuma et al as opposed to a 0.16%
phosphorus diet used during the PTH infusion in ourin a reduction in renal function, such a difference was
not observed. In a previous study, Harris et al showed study [22, 60]. In other studies, a high dietary phosphorus
has been shown to reduce the calcemic response to PTHthat the hypercalcemia and hypercalciuria did not reduce
renal function or concentrating ability in phosphate- [23]. In clinical studies, treatment with bisphosphonates
in patients with primary hyperparathyroidism has re-depleted rats and suggested that this was due to de-
creased tubular uptake and tissue concentration of cal- sulted in modest reductions in serum calcium [62, 63],
which often were not sustained [62]. In a study of osteo-cium during the hypercalcemia of phosphate depletion
as compared with other causes of hypercalcemia [55]. porotic women in whom APD was given for at least five
years, serum calcium and PTH values were normal [64].As reported more than 25 years ago by Copp, we also
found that the calcemic response to PTH was less in Furthermore, following ethylenediaminetetraacetic acid
(EDTA)-induced hypocalcemia, the recovery from hy-the group on the phosphate-depleted than the ND [56].
Another study has reported a similar result [57], but the pocalcemia was not different in the APD-treated women
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and resorption of bone in hypophosphatemic rats. J Clin Investthan controls. Thus, this study suggests that even pro-
50:2519–2530, 1971
longed bisphosphonate treatment may not affect PTH- 4. Ivey JL, Morey ER, Baylink DJ: The effects of phosphate deple-
mediated calcium mobilization from bone. tion on bone. Adv Exp Med Biol 103:373–380, 1978
5. Lee DBN, Brautbar N, Walling MW, Carlson HE, Golvin C,As expected, marked hypercalciuria developed in rats
Coburn JW, Kleeman CR: The biochemical indices of experimen-on the LPD [2, 5, 9, 27, 39]. An unexpected finding was tal phosphorus depletion: A re-examination of their physiological
that for a similar degree of hypercalcemia, the magnitude implications. Adv Exp Med Biol 103:381–394, 1978
6. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanab T, Kuro-of hypercalciuria was greater in the LPD group receiving
kawa K: Prevention of enhanced parathyroid hormone secretion,APD. In both groups, serum PTH levels were similarly synthesis and hyperplasia by mild dietary phosphorus restriction
suppressed. Because the urinary calcium represented a in early chronic renal failure in rats: Possible direct role of phospho-
rus. Nephron 70:242–248, 1995collection integrated over 24 hours and the serum cal-
7. Raisz LG, Niemann I: Effect of phosphate, calcium, and magne-cium was a single value, it is possible that serum calcium sium on bone resorption and hormonal responses in tissue culture.
levels may have been higher in the LPD 1 APD than Endocrinology 85:446–452, 1969
8. Bruin WJ, Baylink DJ, Wergedal JE: Acute inhibition of miner-the LPD group during the 24-hour collection period.
alization and stimulation of bone resorption mediated by hypo-Another distinct possibility is that, as suggested by the phosphatemia. Endocrinology 96:394–399, 1975
decreased osteoblast surface in the APD-treated group, 9. Kimmel PE, Watkins DW, Slatopolsky E, Langman CB:
1,25(OH)2D response to combined zinc and phosphorus depletionhigh doses of APD reduced calcium movement into
in rats. Am J Physiol 22:E319–E326, 1990bone, which then resulted in a greater calcium excretion. 10. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ: Bis-
In summary, this study shows that phosphate depletion phosphonates act on rat bone resorption through the mediation
of osteoblasts. J Clin Invest 91:2004–2011, 1993in the growing rat induced hypercalcemia, hypophospha-
11. van Breukelen FJM, Bijvoet OLM, Frijlink WB, Sleeboom HP,temia, hypercalciuria, and hypophosphaturia, and these
Mulder H, van Oosterom AT: Efficacy of amino-hydroxyproyli-
results were not affected by the administration of the dene bisphosphonate in hypercalcemia: Observations on regulation
of serum calcium. Calcif Tissue Int 34:321–327, 1982bisphosphonate APD. Moreover, the calcemic response
12. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-to PTH was decreased in phosphate-depleted rats. Al-
Nienhuys PJ: Efficacious management with aminobisphosphonate
though the administration of APD reduced the osteo- (APD) in Paget’s disease of bone. Clin Orthop 217:79–98, 1987
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bedrest by alendronate. J Bone Miner Res 10:655–662, 1995
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